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Abstract
Background: Yersinia enterocolitica (YE) is the causative agent of yersiniosis. YE encompass strains of diverse 
pathogenicity: YE biotypes 1B and 2-5 are considered pathogenic, whereas biotype 1A is in general considered 
nonvirulent. Also YE-like species, which can sometimes be misidentified as YE, are considered nonvirulent.
Methods: In order to study differences in clinical picture caused by different YE types and their possible sources a case-
control study was conducted in 2006. In this case-control study, 295 case-patients with YE or YE-like finding and their 
758 controls responded to the questionnaire about symptoms and possible sources of infection.
Results: Strains of pathogenic YE bio/serotypes 3-4/O:3 or 2/O:9 were found in 18%, YE biotype 1A in 65% and YE -like 
strains of 17% of the patients. Patients infected with the strains of pathogenic YE bio/serotypes were younger and had 
fever more often than those with BT 1A who suffered more from vomiting. Symptoms of reactive arthritis were 
reported by 10% of pathogenic YE infections, 3% of YE BT 1A, and 0.3% of the controls. Eating or tasting raw or medium 
done pork was a significant risk factor for pathogenic YE bio/serotype infection (OR 6.6; 95% CI 1.7-24.9) as well as 
eating in a canteen (OR 3.5; 95% CI 1.6-7.9). Imported fruits and berries were associated with increased risk of YE BT 1A 
finding.
Conclusions: The symptoms of the patients with YE BT 1A differed from yersiniosis caused by the classic pathogenic 
YE bio/serotypes. In addition, the patients with YE BT 1A had more protracted gastrointestinal disorders and unspecific 
complaints. Small children were overrepresented in classic pathogenic bio/serotypes while in BT 1A or YE-like species 
were not found among children younger than two years. This suggests the lacking virulence of the BT 1A strains. We 
can not, however, rule out the possibility that some strains of genetically heterogeneous group of BT 1A may cause an 
illness.
Background
Yersinia enterocolitica (YE) is a zoonotic bacterial species
that causes food-transmitted infections. The most com-
mon clinical manifestation of a YE infection is self-lim-
ited gastroenteritis, but extraintestinal manifestations
and postinfectious sequelae such as reactive arthritis
occur as well [1]. YE infections are usually sporadic,
although outbreaks have been reported [2-5]. Small
household infection clusters may be more common than
recognized [6]. Pigs are a known reservoir of YE strains
[1] and raw pork products serve as an important vehicle
for infection [7]. For example in Norway, undercooked
pork, sausage products and untreated water have been
associated with YE infections [8]. In the United States,
contaminated tofu [9] and pasteurized milk [2] were
found to be vehicles for YE in outbreaks.
YE species is divided into six biotypes (1A, 1B, 2, 3, 4,
5), which include several serotypes. The species encom-
passes both pathogenic strains including bio/serotypes 4/
O:3 and 2/O:9 and strains which are classically consid-
ered non-pathogenic, namely strains of biotype (BT) 1A
or non-biotypable strains. Closely related YE-like species,
Y. aldovae, Y. bercovieri, Y. frederiksenii, Y. intermedia, Y.
kristensenii, Y. mollaretii, Y. rohdei, Y. alecksiciae, and Y.
massiliensis, can often be misidentified as YE [10]. YE-
like species are also considered non-pathogenic[1]. How-
ever, several studies that suggest potential pathogenicity
of BT 1A have been published [11-15].
In Finland, YE findings are notifiable and the National
Institute for Health and Welfare (THL), formerly the
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National Public Health Institute (KTL), maintains the
N a t i o n a l  I n f e c t i o u s  D i s e a s e  R e g i s t e r  ( N I D R )  t o  w h i c h
clinical microbiology laboratories report both culture-
and antibody-confirmed yersinia findings. However, lab-
oratories are not required to provide the bio/serotype
information of the YE strains. In Finland, diarrhoeic stool
samples are routinely cultured for presence of Yersinia
strains in addition to Salmonella, Campylobacter and Shi-
gella. Approximately 500 YE cases are reported yearly.
Most of the YE infections are sporadic and only a few ver-
ified outbreaks have occurred in Finland. The most com-
monly notified pathogenic YE bio/serotypes are 4/O:3
and 2/O:9. However, the majority of all the notified find-
ings consist of BT 1A YE and YE-like strains [10]. Correct
identification of the strains that cause clinical symptoms
is important for collecting reliable statistics to benefit
decision-making in health care and food handling sec-
tors. Therefore, we previously reported a laboratory study
where methods to identify all YE isolates accurately
where described [10]. The current case-control study
focuses on symptoms and risk factors of the YE infec-
tions. The aims are to determine the clinical features
caused by different YE bio/serotypes, especially to com-
pare the traditionally pathogenic YE bio/serotypes to YE
BT 1A and to identify the sources of infection in Finland.
Methods
Study design
All Yersinia strains (excluding Y. pseudotuberculosis) iso-
lated from 41,848 stool specimens during January 1st
2006 through December 31st 2006 in 10 clinical microbi-
ology laboratories were collected. Annually these 10 out
of 22 laboratories report approximately two-thirds of all
Finnish Yersinia  cases. Laboratories were selected from
different geographical locations to represent the whole
Finland. The isolates were forwarded to the Bacteriology
Unit (TABA; formerly Enteric Bacteria Laboratory), THL
for further investigations. Identification of the Yersinia
strains were described in detail earlier [10]. The amount
of yersinia in stool samples was estimated semi-quantita-
tively by detecting growth on four streaking areas of CIN
primary culture plates. If colonies that morphologically
resembled Yersinia strains were detected only on the 1st
streaking area or only after cold-enrichment, the amount
of Yersinia bacteria in stool of a patient was estimated to
be low. If there were colonies on the 2nd, 3rd or 4th streak-
ing area, the amount was estimated to be high. Bio/sero-
types 3-4/O:3 or 2/O:9 are here called pathogenic YE
types. Two nonbiotypable YE strains were analysed
together with BT 1A strains and they are all here collec-
tively called BT 1A.
During the study period, 462 YE and YE-like strains
isolated from routinely submitted stool samples were
found. Of those isolates, 29 were excluded from the pres-
ent study, because another yersinia isolate from the same
patient had already been included in the study. In addi-
tion, 27 isolates were excluded because also another
microbe from the same patient was reported to NIDR
(Campylobacter in 10 patients, Salmonella in 7, virus in 4,
Shigella  and  Cryptosporidium  in one patient each) or
there was another YE finding within one week to half a
year previously (four patients). Thus, 406 patients were
accepted into this study.
In a case-control study, for each case patient four age-
matched (same month and year of birth, widened if con-
trols not found), gender-matched and geographically-
matched (same municipality of residence) controls were
selected from the Finnish population register every two
weeks. A detailed questionnaire was sent to each case
immediately after their yersinia isolate was received by
TASU. For the cases, questions on exposures covered the
time period of two weeks before the onset of the symp-
toms (or if person had no symptoms, to the time period
two weeks before the stool sample was given). For the
controls, the time period covered two weeks before
answering the questionnaire. A reminder with a new
questionnaire form was sent two weeks later to the case
or the control if there was no response.
The questionnaire included questions related to symp-
toms and sequelae of yersinia infection as well as to spe-
cific exposures including consumption of different food
items and travelling abroad. Questionnaires were identi-
cal for the cases and controls, except the questions con-
cerning the yersinia infection. Instead, controls were
asked if they had had diarrhoea or abdominal cramps
with fever during the previous month or if they had ever
had yersinia infection. Joint symptoms were asked identi-
cally from cases and controls. A probable reactive arthri-
tis in a case or control was defined as swelling with
gleam/redness in a joint and the onset of joint symptoms
reported with the accuracy of 1-3 days.
The study was approved by the Ethics Committee of
THL.
Statistical analysis
Comparisons of age, gender and symptoms between
patients with different bio/serotypes were made using
either two-sample t-tests (age and duration of symptoms)
or chi square test (others). Source analyses were done
using univariate conditional logistic regressions, i.e.
between cases and controls, separately for pathogenic YE
and YE BT 1A. For each source, missing values (due to
missing choice, "unknown" or "do not remember") were
omitted from the analysis. Cases were included in the
source analyses if the onset of symptoms was reported
with the accuracy of 1-3 days and the time from the onset
of symptoms to the stool sample was not longer than six
weeks. Controls were included in the analyses if their caseHuovinen et al. BMC Infectious Diseases 2010, 10:122
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was included. All analyses were made using Stata version
9.2.
Results
Defining the patients to the study
Of the 406 patients, pathogenic YE were found in stool
samples of 74 (18%), BT 1A strains of 263 (65%) and YE -
like strains of 69 (17%) subjects. YE-like strains included
Y. bercovieri, Y. frederiksenii, Y. intermedia, Y. kris-
tensenii, Y. mollaretii and Y. rohdei (table 1). Patients with
pathogenic YE types were younger than patients with
other YE types. Especially small children under two years
of age were overrepresented among patients with patho-
genic YE (16%, 12/74), while none of the BT 1A or YE-like
species were found among children younger than two
years.
For the case-control study, questionnaires were sent to
the 406 case patients and for their 1597 controls (for
some patients it was not possible to find four controls). In
total, 301 of 406 cases (74%) and 1002 of 1597 controls
(62%) returned the questionnaire. Only those strata with
at least one case and control were useable. Thus 295 cases
(73%) and 758 controls (47%) were included. On average
each case had 2.6/4 controls (64%). Accepted cases were
younger (p = 0.04), while no significant difference was
found between men and women (p = 0.08).
Among 295 cases included in analysis of the case-con-
trol study, 61 (21%) had a strain of pathogenic YE type,
187 (63%) had YE BT 1A and 47 (16%) had a YE-like
strain. Since YE-like species of the cases comprised of six
different species, the numbers of the cases with any one
species were too small for further analyses. Therefore, the
analyses were done only among cases with pathogenic
(bio/serotypes 3-4/O:3 or 2/O:9) or YE BT 1A (BT 1A or
non-biotypable) and their controls.
Symptoms
Almost all cases (240/248) had at least one of the five
symptoms asked (i.e. diarrhoea, fever, stomach cramps,
vomiting or blood in stools). One of the 61 cases (2%)
with pathogenic YE and 7 of 187 cases (4%) with BT 1A
reported having had none of these symptoms. Time from
the onset of the symptoms to the stool sample varied
widely among patients with BT 1A and 40% of them were
unable to define the accurate onset of symptoms (T able
2).
To decrease the recall bias we analysed only the symp-
toms of the cases with different bio/serotypes among
those who were able to report the accurate onset of symp-
toms (1-3 days) and whose sample was taken within six
weeks from onset of symptoms. With these criteria 54/61
(89%) cases with pathogenic YE and 98/187 (52%) cases
with YE BT1A finding were included to the symptom
analyses. Diarrhoea (91%) and stomach cramps (89-92%)
were the most common symptoms, with no difference
between the cases with pathogenic YE or BT 1A (Figure
1). Fever was more common among cases with patho-
genic YE than among those with BT 1A (67% and 35%
respectively P < 0.001). One third of the cases with BT 1A
reported vomiting while among those with pathogenic
type vomiting was rare (33% and 4% respectively P <
0.001). The amount of bacteria was high in 66% (38/58) of
stool samples with pathogenic YE while with BT 1A high
amounts were found only in 19% (35/184) of stool sam-
ples. However, within the different bio/serotypes the
occurrence of symptoms was not associated with high
amount of bacteria detected in stool samples (data not
shown).
Of the 758 controls responding to the questionnaire,
127 (17%) reported having had diarrhoea and 16 (2%)
having had abdominal cramps with fever during the pre-
Table 1: Yersinia strains isolated from 406 patients by bio/serotype and demographical characteristics of the patients, 
Finland, 2006.
Number of strains (%) Mean age, years (min max) Proportion of men N (%)
Y. enterocolitica
3-4/O:3 or 2/O:9 74 (18%) 32 (0.6-80) 41 (55%)
1A or non-biotypable 263 (65%) 50 (2-99) * 98 (37%) *
Y. enterocolitica- like species
Y. bercovieri 17 (4%) 44 (5-81) * 3 (18%) *
Y. frederiksenii 26 (6%) 42 (3-73) 10 (38%)
Y. intermedia 8 (2%) 68 (40-87) * 5 (63%)
Y. kristensenii 4 (1%) 48 (23-79) 2 (50%)
Y. mollaretii 12 (3%) 62 (26-93) * 2 (17%) *
Y. rohdei 2 (0.5%) 55 (47-63) 1 (50%)
* p < 0.05 for the difference compared to YE bio/serotypes 3-4/O:3 or 2/O:9Huovinen et al. BMC Infectious Diseases 2010, 10:122
http://www.biomedcentral.com/1471-2334/10/122
Page 4 of 9
vious month. Nine controls (1%) reported of previous
yersinia infection. No other intestinal bacteria were
reported to NIDR for controls during the previous five
months.
38% of the cases with pathogenic YE and 45% of the
cases with BT 1A reported having had at least one joint
symptom (ache, pain associated to motion, swelling or
gleam/redness). Also 30% of the controls reported at least
one joint symptom. When only those reporting the onset
of joint symptoms at least with the accuracy of 1-3 days
were considered, the prevalence of joint symptoms was
lower, especially among controls (4%). Among cases with
pathogenic YE this proportion was 28% and among cases
with BT 1A it was 20%. Six cases with pathogenic YE type
Table 2: The time from onset of symptoms to stool sample taking.
Time from the onset of 
symptoms to sample taking
Bio/serotype 3-4/O:3 or 2/O:9 Biotype 1A p-value1
0 - 2 weeks 61% (37/61) 36% (67/187)
2 - 4 weeks 20% (12/61) 11% (20/187)
4 - 6 weeks 8% (5/61) 6% (11/187)
Over 6 weeks 0 8% (15/187)
Not known2 11% (7/61) 40% (74/187)
mean:(min- max) 3 12 days:(1-39) 25 days:(0 -360) P = 0.03
1 P for the difference between YE bio/serotypes 3-4/O:3 or 2/O:9 and biotype 1A
2 No date or inexact date for the onset of symptoms or sample taken before symptoms began
3Subjects with not known onset of symptoms excluded
Figure 1 Symptoms of the patients. Symptoms among the subjects, from whom YE were isolated at the latest six weeks from the beginning of 
symptoms. Subjects with missing or unclear answers were excluded. *Statistically significant difference between bio/serotypes 3-4/O:3 or 2/O:9 and 
BT1A (P < 0.001).Huovinen et al. BMC Infectious Diseases 2010, 10:122
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(10%), five cases with BT 1A (3%) and two controls (0.3%)
had probable reactive arthritis.
Self-reported gastro-intestinal diseases were common
among cases with BT 1A (24%), compared to only 10%
among cases with pathogenic YE (7% and 6% among their
controls respectively). Continuous diarrhoea was com-
mon among cases with BT 1A (20%), while among cases
with pathogenic YE and all controls it was rare (2-3%).
Special diets were more common among cases with BT
1A than among their controls, especially they used more
often diet low in lactose (25%) compared to their controls
(15%).
Sources
Cases with the defined onset of symptoms (54 cases with
pathogenic YE type and 98 with BT 1A) and their con-
trols (133 and 251 respectively) were included in the risk
factor analyses. For each source, missing, unknown and
'do not remember' answers were omitted from the analy-
sis.
Eating or tasting raw or medium done pork was a sig-
nificant risk factor for pathogenic YE infection (OR 6.6:
95% CI 1.7-24.9). Non-pasteurized milk products
increased the risk of infection but this effect was not sta-
tistically significant. Eating outside home was associated
with the pathogenic YE infection, both eating in a restau-
rant or in a canteen-type place increased the risk (Table
3). Travelling abroad was associated with the pathogenic
YE infections. Forty-one percent (22/54) of the patients
with the pathogenic YE strain reported having travelled
abroad during the two weeks preceding the onset of
symptoms, but only 8% (10/133) of their controls. Of the
patients with the pathogenic YE who had travelled
abroad, 23% (5/22) had travelled outside Europe, com-
pared to 11% (1/9) of their controls.
Imported fruits and berries were the only food associ-
ated with increased risk of YE BT 1A finding, while eating
game, pasteurized milk and milk products, some vegeta-
bles and domestic berries decreased the risk. Those who
rarely washed vegetables were in increased risk of YE BT
1A. Eating in restaurant (OR 2.8: 95% CI 1.6-4.9) and in
cafeteria (1.8: 1.0-3.0) increased risk of BT 1A finding.
Traveling abroad was more common among patients with
BT 1A (37%, 36/97) than in their controls (8%, 21/248).
Countries outside Europe were a common destination, in
49% (17/35) of journeys of patients with BT 1A compared
to 15% (3/21) of their controls.
Discussion
Majority (65%) of the culture-confirmed YE findings in
the present study were of BT 1A. Bio/serotypes 3-4/O:3
or 2/O:9 were found in 18% of the patients. This agrees
with BT 1A prevalence found in Switzerland and Great
Britain, where majority (60% and 53%, respectively) of the
human YE findings were of BT 1A [12,16]. The role of YE
BT 1A in causing human disease has been debated [11-
15,17-19]. The mechanisms behind the potential patho-
genicity of this biotype have remained unclear, since YE
BT 1A usually lack the classical virulence markers of Yers-
inia virulence plasmid pYV and functional chromosomal
virulence genes [19].
Majority of the patients with pathogenic YE had diar-
rhoea, stomach cramps and fever, while vomiting was
rare. This agrees with the typical clinical picture of yers-
iniosis. The symptoms of patients with YE BT 1A differed
from those of pathogenic biotypes by having less often
fever and more often vomiting. This is in contrast with a
study where illness experienced by patients with BT 1A
was indistinguishable from that caused by pathogenic YE
[12]. The higher frequency of vomiting among patients
with YE BT 1A might be due to enterotoxin YstB known
to be produced by some BT 1A strains [20]. Alternatively,
vomiting among patients with YE BT 1A, may suggest
that the symptoms were due to some other reason, poten-
tially to viral infection and YE was found just by chance.
Viral enteritis is a common disease but in protracted gas-
trointestinal diseases, stool samples are usually investi-
gated for bacterial enteropathogens and for certain
parasites, but viruses are rarely searched for.
Time from the onset of symptoms to the stool sample
varied a lot among patients with YE BT 1A, whereas
among patients with pathogenic YE it was less than two
weeks in majority of the cases, the longest reported time
being 39 days. About half of the patients, irrespective of
the YE bio/serotype found, informed that the stool sam-
ple was taken due to protracted gastrointestinal symp-
toms. This may be a sign of a persistence of the YE
infections. In a Norwegian study it was found that both
adults and children carried YE in the stool for extended
periods [21]. The patients with YE BT 1A strain had more
prolonged gastrointestinal disorders than their controls.
These findings suggest that some BT 1A strains may have
an adverse effect on gastrointestinal tract and possibly
worsen chronic gastrointestinal symptoms or the
patient's immune system may already be compromised.
This agrees with an observation that patients with non-
steroid anti-inflammatory drug-induced colitis had a rel-
atively high prevalence of YE [22]. Genetic differences
among YE BT 1A strains that may be linked to their viru-
lence have also been reported [12,23,24]. Also we have
detected several genetically different subgroups among
the YE BT 1A strains included in the present study
(unpublished results).
The number of reported joint symptoms in our study
was high among both cases and controls. A high number
of joint symptoms among controls have been detected in
other population-based studies earlier [25]. However,
when we limited the typical symptoms of reactive arthri-Huovinen et al. BMC Infectious Diseases 2010, 10:122
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Table 3: Risk factors of YE bio/serotype 3-4/O:3 or 2/O:9 and biotype 1A finding, Finland, 2006.
3-4/O:3 or 2/O:9 Biotype 1A
Number of cases and 
controls1
54 cases
133 controls
98 cases
251 controls
exposed/all1
-cases
-controls
OR (95%CI) 2 exposed/all1
-cases
-controls
OR (95%CI) 2
Traveling
-abroad 22/54
10/133
39.4(5.2-296.7)* 36/97
21/248
8.0(3.8-16.9)*
-in Finland 8/54
38/133
0.5(0.2-1.0) 21/97
78/246
0.6(0.3-1.0)
Eating outside home
-in a restaurant, coffee 
house etc. 3
48/53
95/130
6.1(1.4-27.2)* 72/93
164/242
1.8(0.9-3.7)
-in a staff , school or 
daycare canteen
22/48
30/127
3.5(1.6-7.9)* 36/87
78/232
1.5(0.8-2.7)
Meat and meat 
products:
-pork (well done) 46/51
119/132
1.2(0.4-3.4) 84/93
222/239
0.7(0.3-1.6)
-pork (medium or raw) 10/41
4/108
6.6(1.7-24.9)* 3/66
14/166
0.2(0.0-1.6)
-bovine (well done) 42/51
110/132
1.0(0.4-2.5) 77/90
206/233
0.8(0.4-1.7)
-bovine (medium or 
raw)
10/40
18/110
1.6(0.6-4.3) 14/64
38/173
1.0(0.5-2.2)
-salami 23/51
66/126
0.8(0.4-1.5) 38/86
119/222
0.7(0.4-1.2)
-poultry 48/51
111/126
3.1(0.7-13.8) 81/90
207/240
1.3(0.6-2.9)
-sheep 6/45
17/117
1.6(0.5-5.0) 7/81
22/203
0.8(0.3-2.0)
-game 9/49
25/124
0.8(0.3-2.0) 14/86
65/226
0.5(0.2-0.9)*
Milk and milk 
products
-pasteurized 47/52
124/129
0.3(0.1-1.5) 88/97
241/249
0.4(0.1-1.0)*
-unpasteurized 10/46
13/123
2.4(0.9-6.2) 8/85
30/218
0.6(0.2-1.3)
Soybean and 
soybean products
6/49
22/126
0.6(0.2-1.6) 15/87
37/227
1.2(0.6-2.4)
Fruits and berries
-domestic 37/52
105/128
0.6(0.3-1.3) 75/89
221/243
0.6(0.3-1.3)
-imported 46/53
112/127
0.9(0.3-2.4) 91/95
210/239
3.5(1.2-10.5)*
Vegetables
-roots4 35/49
100/129
0.9(0.4-2.0) 77/89
200/237
1.4(0.7-2.9)Huovinen et al. BMC Infectious Diseases 2010, 10:122
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tis, swelling with gleam/redness with being able to report
the accurate onset of symptoms were found these symp-
toms with 10% pathogenic YE bio/serotypes, 3% YE BT
1A and 0.3% of controls. Still, it is possible that symptoms
of reactive arthritis may have appeared to some patients
only after they had already answered the questionnaire.
Small children were overrepresented among patients
with pathogenic YE and only pathogenic YE strains were
found in children younger than two years. The associa-
t i o n  o f  p a t h o g e n i c  Y E  w i t h  s m a l l  c h i l d r e n  h a v e  b e e n
shown in earlier studies [26-28]. Whether there are spe-
cific risk factors for small children or whether their
immature immune system increases the risk of infection
could not be defined in this study. A Swedish study found
the use of baby's dummy, contact with domestic animals,
eating treated sausage or food prepared from raw pork
products as risk factors for YE infection in children [29].
However, the YE BT 1A seems not to be associated with
small children. Since children are known to be more sus-
ceptible to enteric infections due to immature immune
system [30], this observation implies that YE BT 1A
unlikely causes a disease in otherwise healthy persons.
The results of the study show that the sources for
pathogenic YE and YE BT 1A were different. Eating or
tasting raw or medium done pork was significantly asso-
ciated with finding of pathogenic YE bio/serotypes while
no association with finding of YE BT 1A was found. Pork
has also been the major source of pathogenic YE infec-
tions in earlier studies [1,7,31]. Sources of YE BT 1A has
been shown to be very diverse e.g. water, vegetables, and
different animals [16,19,32]. Pasteurized milk has been
associated with YE infections [2], but we found an associ-
ation with non-pasteurized milk products. In our study
pasteurized milk products were used less by patients with
BT 1A than by their controls.
Analyses on possible sources were restricted due to the
small number of pathogenic YE strains in our study. A
problem in tracing the sources in a questionnaire study
was caused by the time delay from the infection to
answering of the questionnaire. Patients were enquired of
the possible sources of their YE infection in a two-week
period before the onset of symptoms. For the controls, on
the other hand, the questions concerned the time period
two weeks before answering the questionnaire. The time
from the onset of symptoms to responding the question-
naire varied a lot among patients and many could not
report the exact time of the onset of symptoms. To con-
trol these differences and to minimize recall bias we
-lettuce and cabbage5 44/52
112/129
1.0(0.4-3.0) 84/96
229/240
0.3(0.1-0.8)*
-onion and leek 35/50
98/130
0.8(0.4-1.9) 63/91
193/237
0.5(0.3-1.0)*
-cucumber, tomato, 
pepper
49/53
127/130
0.2(0.0-1.5) 94/96
245/247
0.4(0.0-5.1)
Washing vegetables 6
-washing roots 38/39
112/116
0.9(0.1-9.8) 69/72
217/224
0.2(0.0-1.4)
-washing pre-washed 
roots
34/35
102/108
1.6(0.2-14.3) 60/68
196/206
0.2(0.0-0.6)*
-pealing roots 36/39
98/113
2.2(0.6-8.2) 66/73
185/216
1.3(0.5-3.3)
-washing vegetables 
other than roots
42/43
112/119
2.7(0.3-23.0) 69/75
223/231
0.1(0.0-0.7)*
-washing pre-washed 
vegetables other than 
roots
33/36
101/111
1.3(0.3-5.1) 51/62
196/206
0.1(0.0-0.4)*
1Cases were included to the source analyses if the onset of symptoms was reported with the accuracy of a couple of days and time from the 
onset of symptoms to the stool sample was not longer than six weeks. Controls were included if their case was included. For each source 
group, missing values were omitted per analysis.
2Only those strata with at least case and one control having non-missing values were included to logistic regression analyses. These omissions 
were done separately per source.
3Restaurant, coffee house, hamburger restaurant, chip shop, pizzeria, service station restaurant, snack bar
4Carrot, Swedish turnip, radish
5White cabbage, red cabbage, cauliflower, lettuce, iceberg lettuce, Chinese cabbage
6exposed are those who washed vegetables usually or always, compared to those washing them only rarely
* Statistically significant result
Table 3: Risk factors of YE bio/serotype 3-4/O:3 or 2/O:9 and biotype 1A finding, Finland, 2006. (Continued)Huovinen et al. BMC Infectious Diseases 2010, 10:122
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i n c l u d e d  i n  t h e  a n a l y s i s  o n l y  c a s e s  w h o  r e p o r t e d  t h e
onset of symptoms accurately and who have had at most
six weeks from the onset of symptoms to sample taking.
Conclusions
The majority of YE strains isolated from Finnish patients
belonged to BT 1A. The symptoms and sources of
patients with YE BT 1A were different from the patho-
genic YE. In addition, BT 1A patients had more unspe-
cific complaints and protracted gastrointestinal
disorders, which suggest that the original cause of the ill-
ness may have been other than YE BT 1A. This is sup-
ported by the fact, that we did not find any YE BT 1A
strains in small children. However, it is still possible that
in the highly heterogeneous group of YE BT 1A there are
subgroups that can cause a disease, but this needs further
investigations. While the significance of the YE BT 1A
strains remains unclear, the correct registering of infec-
tions caused by the truly pathogenic YE strains is essen-
tial for health protection purposes.
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